The researchers also noted that 23.5% (95% CI, 22.3-24.8) of people meeting FDA indications for tirzepatide reported using medications that may slow gastrointestinal motility, which could increase gastrointestinal adverse effects when combined with any GLP-1 receptor agonist
Testosterone therapy, long used in men to build muscle, is increasingly recognized as an option for some women
Review weight change, glycemic control, gastrointestinal symptoms, hypoglycemia risk, hydration status, pancreatitis history, gallbladder symptoms, and medication adherence
It can cause an average 20% reduction in weight
Pownall HJ, Schwartz AV, Bray GA, Berkowitz RI, Lewis CE, Boyko EJ, et al